Accu-Break Pharmaceuticals

Executive Summary

Accu-Break Pharmaceuticals, headquartered in Fort Lauderdale, FL, is a privately held drug delivery company specializing in scored tablets designed for precise dose division. Founded in 1960, the company addresses a critical safety need: enabling patients to accurately split tablets for flexible dosing while minimizing medication errors. Their proprietary technology ensures consistent breakability, which is particularly valuable for chronic conditions requiring dose titration, such as cardiovascular or psychiatric disorders. Despite its small size (1–10 employees) and limited public visibility, Accu-Break occupies a defensible niche in pharmaceutical manufacturing. The aging population and growing emphasis on personalized medicine support demand for flexible dosing solutions. However, the company lacks disclosed financials, partnerships, or recent pipeline updates, suggesting a low-profile commercial focus. Competitive advantages include long-standing expertise and potential regulatory barriers for generic alternatives. Growth opportunities hinge on licensing deals or adoption by larger pharma firms seeking to enhance their solid-dose offerings.

Upcoming Catalysts (preview)

• Q4 2026New Licensing Agreement with Major Pharmaceutical Partner30% success
• Q1 2027FDA Guidance Update on Tablet Scoring Requirements20% success
• TBDLaunch of Enhanced Breakability Technology Platform15% success